2-(Tert-butylamino)-6-fluorobenzonitrile | 1368622-56-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(Tert-butylamino)-6-fluorobenzonitrile
• CAS: 1368622-56-3
• 化学式: C₁₁H₁₃FN₂
• 分子量: 192.236
• InChiKey: RFJSASKIKJLURK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  碳酸胍 、 2-(Tert-butylamino)-6-fluorobenzonitrile 以 N,N-二甲基乙酰胺 为溶剂， 反应 8.0h， 以78%的产率得到N5-tert-butylquinazoline-2,4,5-triamine
  参考文献：
  名称：

  Discovery and Optimization of 2,4-Diaminoquinazoline Derivatives as a New Class of Potent Dengue Virus Inhibitors

  摘要：

  The results of a high-throughput screening assay using the DENV-2 replicon showed that the 2,4-diaminoquinazoline derivative 4a has a high dengue virus inhibitory activity (EC50 = 0.15 mu M). A series of 2,4-diaminoquinazoline derivatives based on 4a as a lead compound were synthesized and subjected to structure-antidengue activity relationship studies. Among the series of 2,4-diaminoquinazoline derivative probed, 4o was observed to display both the highest antiviral potency (EC50 = 2.8 nM, SI > 1000) and an excellent pharmacokinetic profile.

  DOI：

  10.1021/jm2015952
• 作为产物：
  描述：

  2,6-二氟苯腈 、 叔丁胺 在 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 0.25h， 以76%的产率得到2-(Tert-butylamino)-6-fluorobenzonitrile
  参考文献：
  名称：

  Discovery and Optimization of 2,4-Diaminoquinazoline Derivatives as a New Class of Potent Dengue Virus Inhibitors

  摘要：

  The results of a high-throughput screening assay using the DENV-2 replicon showed that the 2,4-diaminoquinazoline derivative 4a has a high dengue virus inhibitory activity (EC50 = 0.15 mu M). A series of 2,4-diaminoquinazoline derivatives based on 4a as a lead compound were synthesized and subjected to structure-antidengue activity relationship studies. Among the series of 2,4-diaminoquinazoline derivative probed, 4o was observed to display both the highest antiviral potency (EC50 = 2.8 nM, SI > 1000) and an excellent pharmacokinetic profile.

  DOI：

  10.1021/jm2015952

文献信息

• Androgen Receptor Modulators
  申请人：Wang Jiabing

  公开号：US20070269405A1

  公开（公告）日：2007-11-22

  Compounds of structural Formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

  结构式（I）的化合物以组织选择性的方式调节雄激素受体（AR），在增强肌肉张力和治疗由雄激素缺乏引起的或可以通过雄激素治疗改善的疾病中有用，包括骨质疏松症，骨质疏松症，糖皮质激素诱导的骨质疏松症，牙周病，骨折，骨重建手术后的骨损伤，肌肉萎缩，虚弱，老化皮肤，男性性腺功能减退，女性绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖症，再生障碍性贫血和其他造血系统疾病，炎性关节炎和关节修复，艾滋病浪费，前列腺癌，良性前列腺增生症（BPH），腹部脂肪堆积，代谢综合征，2型糖尿病，癌症恶病质，阿尔茨海默病，肌肉萎缩症，认知能力下降，性功能障碍，睡眠呼吸暂停，抑郁症，早发卵巢衰竭和自身免疫疾病，单独或与其他活性药物联合使用。
• US7482359B2
  申请人：——

  公开号：US7482359B2

  公开（公告）日：2009-01-27
• Discovery and Optimization of 2,4-Diaminoquinazoline Derivatives as a New Class of Potent Dengue Virus Inhibitors
  作者：Bo Chao、Xian-Kun Tong、Wei Tang、De-Wen Li、Pei-Lan He、Jean-Michel Garcia、Li-Min Zeng、An-Hui Gao、Li Yang、Jia Li、Fa-Jun Nan、Michael Jacobs、Ralf Altmeyer、Jian-Ping Zuo、You-Hong Hu

  DOI：10.1021/jm2015952

  日期：2012.4.12

  The results of a high-throughput screening assay using the DENV-2 replicon showed that the 2,4-diaminoquinazoline derivative 4a has a high dengue virus inhibitory activity (EC50 = 0.15 mu M). A series of 2,4-diaminoquinazoline derivatives based on 4a as a lead compound were synthesized and subjected to structure-antidengue activity relationship studies. Among the series of 2,4-diaminoquinazoline derivative probed, 4o was observed to display both the highest antiviral potency (EC50 = 2.8 nM, SI > 1000) and an excellent pharmacokinetic profile.